The United States of America, as Represented by the Secretary, Department of Health and Human Services

Fintan R Steele

Ignacio R Rodriguez

Lincoln V Johnson

Gerald J Chader

Joyce Tombran-Tink

Sofia Patricia Becerra

S Patricia Becerra

The present invention relates to a purified retinal pigmented epithelium derived neurotrophic factor composition and a method for purifying such a retinal pigmented epithelium neurotrophic factor. The present invention also relates to a recombinant DNA molecule comprising a gene encoding a retinal pigmented epithelium derived neurotrophic factor having the DNA sequence or the amino acid sequence in SEQ ID NO:1 and to an organism transformed with the recombinant DNA molecule. In addition, the present invention relates to a method of treating tumors, ocular diseases, nerve injuries, and conditions resulting from the activity of serine proteases, which comprises administering PEDF.

Retinal pigmented epithelium derived neurotrophic factor

Nucleic acids encoding the neurotrophic protein known as pigment epithelium derived factor (PEDF), a truncated version of PEDF referred to as rPEDF, and equivalent proteins, vectors comprising such nucleic acids, host cells into which such vectors have been introduced, recombinant methods for producing PEDF, rPEDF, and equivalent proteins, the rPEDF protein and equivalent proteins of rPEDF and PEDF-BP, -BX and BA, and the PEDF protein produced by recombinant methods. Effects and uses of these variants on 1) neuronal differentiation (neurotrophic effect) 2) neuron survival (neuronotrophic effect) and 3) glial inhibition (gliastatic effect) are described.

Pigment epithelium-derived factor: sequence of the PEDF gene

Retinal pigmented epithelium derived neurotrophic factor and methods of use

Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene

Growing community of inventors

Washington, DC, United States of America

Fintan R Steele